-
The Future Pattern of Biosimilars in China
zhulikou431
March 02, 2018
The biosimilars in China have entered the fast lane of development, and CFDA is now open to and encouraging biosimilar R&D...
-
Opdivo May Be the First Marketed in China, Chinese Pharmaceutical Enterprises are Catching up Fast!
Zhixing
January 17, 2018
Anti-PD-1 monoclonal antibodies are very popular with pharmaceutical enterprises, however, it is hard to find such monoclonal antibody in China.
-
Shire expands broad monoclonal antibody research platform
cphi-online
July 20, 2017
Shire obtains worldwide license to pursue development and commercialization of a novel, potentially differentiated, pre-clinical bi-specific antibody candidate for Hemophilia A.
-
When Will Chinese “Rituxan” be Marketed in Compete with More Than a Dozen Applying for anti-CD20
en-cphi.cn
July 14, 2017
CFDA released the 2016 Annual Report of Release of Biological Products written by the National Institutes for Food and Drug Control of China on July 4, which has made statistics of biological products included in release management.
-
AstraZeneca Updates Stratos 1 Phase III Trial of Tralokinumab
americanpharmaceuticalreview
May 11, 2017
AstraZeneca and MedImmune announced tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody.
-
Glenmark Pharma initiates clinical investigation for GBR 310
financialexpress
April 26, 2017
GBR 310 is a recombinant DNA-derived humanised immunoglobulin G1 kappa monoclonal antibody
-
Sanofi and Lonza in $285mn Biologics Pact
contractpharma
March 07, 2017
A large-scale facility, to be built in Visp, Switzerland, will be established through a joint venture
-
Sanofi, MedImmune in RSV Alliance
contractpharma
March 06, 2017
MedImmune to lead development, AstraZeneca retains manufacturing activities, Sanofi-Pasteur will lead commercialization
-
Fujifilm Diosynth Biotechnologies Launches New Service Offering
contractpharma
March 03, 2017
Will support development and cGMP monoclonal antibody production
-
Sanofi, Lonza join hands to build biologics plant
biospectrumasia
March 01, 2017
The joint venture combines the strong biologics development pipeline of Sanofi with the expertise of Lonza to design, construct, start-up and operate a state-of-the-art large-scale mammalian cell culture facility